Autoimmunity
Autoimmunity represents an area of high unmet medical need, with few validated targets. TScan’s target discovery platform provides a way to identify the targets of pathogenic T-cells in autoimmune disease, unlocking the development of targeted therapeutics.
Current therapies for autoimmune disorders typically provide general immune suppression, leading to a risk of serious side-effects for patients.
Target-specific therapies, on the other hand, provide a way to address the cause, rather than the broader symptoms, of autoimmunity.
TScan has identified the targets of pathogenic T-cells in
HLA-B*27-associated autoimmune disorders, including ankylosing spondylitis, and
is evaluating strategic partnerships for this program.
